TABLE 1.
Treatment | Dose/mouse | No. of mice transplanted (donor B6a/PAI-1−/−) | No. of mice surviving 4 weeks | Adverse events |
---|---|---|---|---|
μg | ||||
Saline | 0 | 11 (6 B6/5 PAI-1−/−) | 10 | 1 thrombosis |
NSP | 15 | 5 (0 B6/5 PAI-1−/−) | 4 | 1 thrombosis |
NSP-PP RCL mutant | 15 | 5 (0 B6/5 PAI-1−/−) | 4 | 1 hematoma |
S-1 | 1.5 | 6 (0 B6/6 PAI-1−/−) | 6 | 0 |
S-1 | 15 | 10 (5 B6/5 PAI-1−/−) | 8 | 1 thrombosis, 1 fighting injury |
S-1 | 150 | 4 (0 B6/4 PAI-1−/−) | 4 | 0 |
S-2 | 15 | 5 (5 B6/0 PAI-1−/−) | 4 | 1 thrombosis |
S-3 | 15 | 6 (6 B6/0 PAI-1−/−) | 6 | 0 |
S-4 | 15 | 5 (5 B6/0 PAI-1−/−) | 5 | 0 |
S-5 | 1.5 | 4 (0 B6/4 PAI-1−/−) | 4 | 0 |
S-5 | 15 | 6 (0 B6/6 PAI-1−/−) | 6 | 0 |
S-5 | 150 | 4 (4 B6/0 PAI-1−/−) | 4 | 0 |
S-6 | 1.5 | 6 (6 B6/0 PAI-1−/−) | 6 | 1 thrombosis |
S-6 | 15 | 6 (0 B6/6 PAI-1−/−) | 0 | 6 thromboses |
S-7 | 15 | 5 (0 B6/5 PAI-1−/−) | 5 | 0 |
S-8 | 15 | 5 (0 B6/5 PAI-1−/−) | 5 | 0 |
Total no. of mice | 93 (37 B6/56 PAI-1−/−) | 81 | 12 |
a B6, C57BL/6.